Revised. Amendments from Version 1
==================================

This improved version contains some minor revisions as suggested by peer reviewers.  Throughout the paper, the following changes have been made: Clarity was provided in relation to screening tools. Those utilised by included studies will be reported, they will not be applied by this systematic review. A narrative synthesis is anticipated due to heterogeneity of included study reported outcomes. Definitions for medicines optimisation, clinical pharmacy, deprescribing, and nursing homes were added to the systematic review protocol for clarity.  Operationalisation of the Walshe and Smith framework for integration was provided.  Examples of mental health and clinical physical outcomes have been provided.  Subgroup analysis in relation to age-groups was clarified in the analysis section.  Terms such as \'screening tools\' have been employed to ensure consistency. Exclusion criteria were also refined.

Introduction
============

Patients with multimorbidity and polypharmacy have complex health needs. Polypharmacy has commonly been defined as being on five or more medications, however recent studies have highlighted the rising prevalence of major polypharmacy defined as being on 10 or more medications ^[@ref-2]^. Polypharmacy increases the risk of potentially inappropriate prescribing (PIP) and treatment burden in this patient cohort ^[@ref-3]^. PIP is described as potential sub-optimal prescribing and is typically identified using screening tools such as the Screening Tool of Older People's Prescriptions (STOPP)-Screening Tool to Alert to Right Treatment (START) criteria ^[@ref-4]^, Beers criteria ^[@ref-5]^ or prescribing appropriateness indices ^[@ref-6]^. Medicines optimisation is a broad concept adopted for this systematic review which includes the identification and rectification of potentially inappropriate prescribing as defined by validated screening tools. This is in line with the definition adopted by the NICE guidelines ^[@ref-7]^ on medicines optimisation. "A person-centred approach to safe and effective medicines use, to ensure people obtain the best possible outcomes from their medicines". Medication optimisation can also encompass deprescribing, which is defined as the process of withdrawal of an inappropriate medication, supervised by a health care professional ^[@ref-8]^. Polypharmacy is also associated with adverse drug events, which may create significant cost to both the healthcare system/health service and patients ^[@ref-9]^. An Irish study conducted in 2010 found that an estimated 36% of adult patients over the age of 70 had at least one PIP event. This resulted in an additional €45 million in healthcare expenditures ^[@ref-10]^. "Irrespective of definition or population age, polypharmacy is a major health issue with increasing worldwide prevalence ^[@ref-11]^".

Integration of clinical pharmacists within general practices may be an effective way to address PIP, and implement deprescribing through medication reviews and address challenges with general practice workload ^[@ref-12]^. Evidence suggests that clinical pharmacists improve the quality and safety of prescribing ^[@ref-12]^, and that non-dispensing pharmacists integrated into the primary care setting add value to patient-centred clinical pharmacy services ^[@ref-13]^. Heterogeneity of outcomes reported in systematic reviews tend to make meta-analysis challenging and thus it is unclear whether such interventions can result in clinically significant improvements in patient outcomes. There is evidence to suggest that clinical pharmacist review of medications and pharmacist-physician collaboration results in cost avoidance in the hospital setting, and that such interventions are cost-effective ^[@ref-14]^. However, there is limited evidence to date surrounding the cost-effectiveness of clinical pharmacists integrated within general practice to optimise medications and health outcomes in primary care ^[@ref-12],\ [@ref-14]^. Previous systematic reviews cite heterogeneity in terms of role, and duration and frequency of intervention as a limitation. They also focussed on interventions where the clinical pharmacist and general practitioner (GP) were geographically co-located. This systematic review will differ in that it focuses on patients with multimorbidity and polypharmacy, without a focus on specific conditions. Previous reviews included studies which were single-condition focused, for example diabetes, hypertension, dyslipidaemias, heart failure or depression ^[@ref-12],\ [@ref-13]^. As this review intends to analyse studies relevant to polypharmacy and multimorbidity these studies will not be reported unless they include information on degree of polypharmacy or other morbidities. It will include studies that involve remote clinical pharmacist and GP integration, provided there is on-going collaboration and clear evidence of working together to improve patient outcomes.

The overall aim of this systematic review is to examine the effectiveness of interventions involving the integration of clinical pharmacists within general practice, to improve prescribing practices and health outcomes in primary care settings. We will also examine the cost-effectiveness of such interventions.

Review questions
----------------

What is the effectiveness of interventions integrating clinical pharmacists within general practice on medicines optimisation and health outcomes in adult patients with polypharmacy in comparison to usual care?

Is integrating clinical pharmacists within general practice, to improve medicines optimisation and health outcomes in adult patients with polypharmacy, cost-effective?

Methods
=======

The systematic review will be conducted in line with the PRISMA guidelines ^[@ref-15]^. The protocol will be reported in line with the PRISMA-P guidelines ^[@ref-16]^.

Eligibility criteria
--------------------

***Participants/population.*** Patient participants must be adult patients aged 18 years and over in the primary care setting with polypharmacy as defined by study author. Patients will be excluded if they are younger than 18 years old. Studies must have a majority of patients (≥80%) identified as having polypharmacy (using any definition). The generally accepted definition is five or more routine medicines ^[@ref-2]^.

Clinical pharmacists participating in the intervention must be involved in medicines optimisation roles and integrated physically or remotely as per the definition below, within the primary care setting. The definition of primary care for this review will be; a system which is "integrated, easy to access, health care services by clinicians who are accountable for addressing a large majority of personal health care needs, developing a sustained and continuous relationship with patients, and practicing in the context of family and community" ^[@ref-17]^. Pharmacist interventions in a nursing home, secondary or tertiary care setting will be excluded.

Nursing homes are defined as;

-   "a facility that provides 24-hour functional support for people who require assistance with activities of daily living (ADLs) or instrumental activities of daily living (IADLs) and have identified health needs

-   may or may not be staffed with health care professionals

-   provides long-term care and/or rehabilitation as part of hospital avoidance or to facilitate early hospital discharges

-   does not function as a hospital ward and is not hospital-based

-   may play a role in providing palliative and/or hospice care at end of life" ^[@ref-18]^.

Nursing homes are also known as care homes, long term care facilities and aged-care facilities. Nursing care can be provided on a 24-hour basis in these types of homes. Residential homes, assisted-living, and supportive care facilities provide personal care to residents ^[@ref-19]^. Residents in nursing homes typically require assistance with daily living due to identified health needs but do not require hospital care ^[@ref-18]^.

If the setting is unclear, study authors will be contacted to determine the level of access to care the patients had. If confusion persists after contacting study authors the study will be discussed with the systematic review team and a consensus will be reached.

Integration will be defined as per the framework adapted from Walshe and Smith ^[@ref-20]^. The framework consists of six dimensions; organisational, informational, clinical, financial, functional and normative. Four dimensions of the framework map to the inclusion and exclusion criteria of the review;

1.  The organisational dimension will involve looking at whether the pharmacist is physically co-located with the GP or if the intervention is remote but encompassed within the same network.

2.  The informational dimension refers to integration and access of clinical patient systems.

3.  The clinical dimension will encompass care delivery to patients and communication with GPs.

4.  The functional dimension allows for the capture of other actions taken by pharmacists integrated within GP settings such as medicines education or administrative support.

Data will be extracted where available on the other dimensions;

1.  It is anticipated that the financial dimension will not be measureable as most interventions are externally funded.

2.  Normative dimensions will look at the design of interventions in terms of shared goals and visions of activities involved and desired outcomes.

***Intervention/exposure.*** To be eligible for inclusion, studies must involve a clinical pharmacist optimising medication for patients in a primary care setting through a variety of services. Interventions can be targeted at patient or prescriber behaviours. The relationship between pharmacist and GP can be conducted in a co-located setting or remotely where the pharmacist is not in the same geographical location as the GP. The relationship must be continued for the duration of the intervention. This relationship will be defined as a collaborative relationship where "health care professionals assume complementary roles and cooperatively working together, sharing responsibility for problem-solving and making decisions to formulate and carry out plans for patient care" ^[@ref-21]^. Contact can be face to face, virtual, by telephone or via an online forum once the contact is in real-time.

'Once-off' interventions where the clinical pharmacist does not maintain a relationship with the GP will be excluded. Such interventions will demonstrate a single instance of unidirectional communication of a medication review issue to the GP (e.g. sending a fax or email) with no collaborative follow-up. We will exclude studies with interventions only targeting a single condition unless the intervention addresses all medicines for the patients, not only those medications which are condition specific.

***Comparator/control.*** Usual care in primary care setting.

***Types of studies.*** We will include randomised controlled trials (RCTs), non-randomised controlled trials (nRCTs), controlled before-after (CBA), and interrupted-time-series (ITS) studies using Cochrane Effective Practice and Organisation of Care (EPOC) study design criteria ^[@ref-22]^. Health economic studies including comparative resource use studies and economic evaluations (cost-effectiveness analysis, cost-utility analysis, cost-minimisation analysis and cost-benefit analysis) will also be included.

***Setting.*** Only studies in a primary care setting will be included.

Outcomes
--------

***Main outcomes.*** Potentially inappropriate or high risk prescriptions as reported by included studies. Studies may report potentially inappropriate or high risk prescriptions using screening tools such as; STOPP/START ^[@ref-4]^ and Beers criteria ^[@ref-5]^ (explicit criteria), or the Medicines Appropriateness Index ^[@ref-23]^ and Prescribing Appropriateness Index ^[@ref-24]^ (implicit criteria).

Number of medicines. The number of medicines as reported by included studies. The definition of this may vary across studies (e.g. some may use the number of repeat medicines), however where possible we will use the number of medicines including acute and repeat prescription medicines.

***Additional outcomes.***

-   Patient reported outcomes measures (PROMs): For example, Health Related Quality of Life measured using standardised questionnaires such as EQ-5D, SF-12, SF-36.

-   Adverse events or harms, for example measured using the adverse drug withdrawal reaction scale ^[@ref-25]^.

-   Health service utilisation (including GP visits, emergency department (ED) visits, outpatient clinic attendances, inpatient admissions, other healthcare professional appointments).

-   Relevant clinical physical outcomes would include measures such as blood pressure, glycosylated haemoglobin as a measure of blood glucose control, serum/blood cholesterol measurement and mortality.

-   Mental health outcomes such as depression can be captured using screening tools such as the Warwick Edinburgh Mental wellbeing scale, the Hospital Anxiety and Depression Scale or the Beck Depression Inventory.

1.  These lists are not exhaustive and heterogeneity between studies in terms of outcomes reported is anticipated.

-   Economic evaluations;

    1.  Direct costs

    2.  Incremental cost-effectiveness ratio (ICER)

    3.  Cost per unit of effect

    4.  Quality-adjusted life years (QALYs) and disability-adjusted life years (DALYs)

    5.  Cost differences (in measured in cost-benefit / cost-minimisation analysis)

    6.  Other economic measures where data available.

Search strategy
---------------

The following databases will be searched from inception to October 2019; [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/), [Cochrane Library](https://www.cochranelibrary.com/), [Cochrane Central Register of Controlled Trials](https://www.cochranelibrary.com/central/about-central), [EMBASE](https://www.embase.com/login), [Web of Science](https://apps.webofknowledge.com/WOS_GeneralSearch_input.do?product=WOS&search_mode=GeneralSearch&SID=D3l81bxsbEG4X11SEIM&preferencesSaved=), [SCOPUS](https://www.scopus.com/search/form.uri?display=basic), [Lilacs](https://lilacs.bvsalud.org/en/) and [CINAHL](https://www.ebscohost.com/nursing/products/cinahl-databases/cinahl-complete).

For the cost-effectiveness evaluation the following databases will be searched: NHS Economic Evaluations Database (NHS EED) and the Health Technology Assessment (HTA) database (searchable from the [University of York Centre for Reviews and Dissemination site](https://www.crd.york.ac.uk/CRDWeb/)). For both PubMed and EMBASE an economic filter will be applied.

The search strategy for PubMed will include a combination of keywords and MeSH terms for broad concepts of pharmacy and primary health care. This strategy will be adapted for different databases and terms for cost-effectiveness will be included for the economic evaluation component. A review of reference lists of included studies will also be performed. No language limits will be applied. Search strategy is available as extended data ^[@ref-26]^.

***Data management.*** All citations will be downloaded and stored in [EndNote](https://endnote.com/) reference manager, Version 8. [Rayyan](https://rayyan.qcri.org/welcome) software will be used for the title and abstract screening step ^[@ref-27]^.

***Study selection.*** Titles will be screened for clearly ineligible studies by one researcher (AC). Titles and abstracts will be independently screened by two members of the review panel (AC and OJ) to identify studies that potentially meet inclusion criteria outlined above, following duplication removal. Studies which do not meet the inclusion criteria will be excluded at this stage. If studies are unclear or if they meet inclusion criteria, they will be selected for full text review. Where disagreement arises between reviewers, a third reviewer will be consulted (FM). A PRISMA flow chart will be used to display the flow of identified studies through the review.

Data extraction
===============

Two reviewers (AC and OJ) will use a standardised, pre-piloted form (see extended data ^[@ref-26]^) to perform data extraction of the following information: name of first author, year of publication, country of publication, study setting; study population and participant demographics, intervention details and design, control setting details, recruitment and study completion rates, outcomes and times of measurement.

Economic evaluation data will be extracted as per the [Health Information and Quality Authority](https://www.hiqa.ie/) (HIQA) guidelines for interpretation of economic evaluations in Ireland;

1.  Study question, population, intervention, comparator and setting

2.  Modelling methods

3.  Sources and quality of clinical data

4.  Cost data

5.  Resource usage

6.  Study outcomes

7.  Methods for dealing with uncertainty.

Where disagreement arises between reviewers, a third reviewer will be consulted (SS or FM).

Quality assessment
------------------

Studies will be included if they meet all inclusion criteria irrespective of quality. The risk of bias in all included effectiveness studies will be assessed using standard EPOC criteria ^[@ref-22]^ (EPOC 2015) including the following domains: allocation (sequence generation and concealment); baseline characteristics; incomplete outcome data; contamination; blinding; selective outcome reporting; and other potential sources of bias. Publication bias will be assessed using a funnel plot if ten or more studies are identified.

The economic evaluation studies will be assessed for methodological quality using the CHEC list as per the Cochrane Handbook for critical appraisal of methodological quality ^[@ref-28]^.

***Assessing the quality of the body of evidence.*** The certainty of evidence for each outcome will be assessed, where appropriate, using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria and [GRADEPro software](https://community.cochrane.org/help/tools-and-software/gradepro-gdt) ^[@ref-29]^.

Strategy for data synthesis
---------------------------

A narrative synthesis is anticipated for effectiveness studies. Similarly, for the economic evaluations a narrative synthesis is anticipated and results displayed in tables.

A statistician will advise if there are sufficient data to support meta-analysis. [RevMan](https://community.cochrane.org/help/tools-and-software/revman-5) 5.3 ^[@ref-30]^ or [Stata](https://www.stata.com/) version 15 ^[@ref-31]^ software will be used. A random effects model will be employed to account for between-study heterogeneity. As per the Cochrane Handbook ^[@ref-32]^ the chi-square test will assess heterogeneity between individual studies. An I ^2^ statistic will assess the impact of heterogeneity on meta-analysis where I ^2^ value greater than 75% indicates significant heterogeneity.

Analysis of subgroups
---------------------

Subgroup analysis will be performed if adequate studies exist for interventions and outcomes.

Subgroup analysis will be based on age of patients (18--65 years vs 65 or older), degree of polypharmacy (\<10 vs 10 or more) and location of intervention (co-located vs remote location), where data allow. The effect of each individual study on the overall estimates of effect size and determinants will be assessed using sensitivity analyses.

Dissemination of information
----------------------------

The review will be published in a relevant peer reviewed journal, reported using the PRISMA guidelines. The review will also be presented at a relevant conference and disseminated to policy-makers, patients, and the public.

Study status
------------

Database searches have been completed and title and abstract screening is currently underway.

Discussion
==========

This systematic review will give an overview of the effectiveness of interventions involving clinical pharmacist integration within general practice, to improve prescribing and health outcomes in patients with polypharmacy and multimorbidity. We will focus on interventions where the clinical pharmacist and GP work collaboratively to improve patient outcomes, whether co-located or remotely. It is intended that this will address patient populations that live in geographically isolated regions in tandem with patients who live in more geographically connected settings.

This systematic review can contribute to the evidence base for managing multimorbidity. Good quality evidence is required to develop guidelines directed at such complex patients and interventions have been focused on the patients who use clinical services most in recent years ^[@ref-17]^. This review focuses on patients with polypharmacy, a factor in treatment burden for patients with multimorbidity. By addressing this issue in the primary care setting this may improve patient outcomes.

This will provide evidence to policy makers on strategies involving pharmacists integrating within general practice settings to address issues which arise in patients with polypharmacy in a primary care setting.

Data availability
=================

Underlying data
---------------

No data are associated with this article

Extended data
-------------

Open Science Framework: The effectiveness of integrating clinical pharmacists within general practice to optimise prescribing and health outcomes in primary care patients with polypharmacy: A protocol for a systematic review. <https://doi.org/10.17605/OSF.IO/38CU5> ^[@ref-26]^

This project contains the following extended data:

-   Data extraction template.xlsx (Excel file containing the data extraction sheet for the study)

-   PubMed Search Strategy.docx (Word document containing the PubMed search strategy)

Reporting guidelines
--------------------

PRISMA-P checklist for "The effectiveness of integrating clinical pharmacists within general practice to optimise prescribing and health outcomes in primary care patients with polypharmacy: A protocol for a systematic review" <https://doi.org/10.17605/OSF.IO/38CU5> ^[@ref-26]^

Data are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](http://creativecommons.org/publicdomain/zero/1.0/) (CC0 1.0 Public domain dedication).

Paul J Murphy MLIS, Information Specialist, Royal College of Surgeons in Ireland Library, 26 York Street, D02 YN77. Advised on search strategies.

Grainne McCabe, Scholarly Communications & Research Support Officer, Royal College of Surgeons in Ireland Library, 26 York Street, D02 YN77. Advised on search strategies.
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Thank you for addressing my comments and revising your manuscript. I am satisfied with the changes made and believe that your response provided added clarity. I have no further comments and I look forward to reading the results of this systematic review.
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Version 1

This is a generally clear, well-written protocol for a systematic review looking at the effectiveness of clinical pharmacists integrated within general practice for polypharmacy management. Overall, the methodology is sound, and the proposed review will hopefully provide a useful appraisal of the evidence.

Additional clarity could be provided around the type of clinical pharmacist in the abstract methods. The title specifically mentions integration of the pharmacist, but I think this should also be explicit in the abstract methods.

Similarly, it may be useful to expand on the definition used for integration, and to perhaps give more details regarding how the Walshe and Smith framework was operationalised, and perhaps clarifying for the reader whether all six dimensions are required without the reader having to refer to the source reference.

Further minor points: Clarify whether \"nursing home\" exclusion includes residential or other supportive care environments that don\'t specifically include nursing, and how situations where the setting is unclear will be dealt with.Outcomes - \"number of medicines\" should ideally be defined (although likely to vary across studies) - will it include both acute and repeat prescriptions, or account for length of treatment (e.g. chronic vs. one-off drugs)?The additional outcome \"clinical outcomes \[physical and mental health\]\" is very vague - some examples might help clarify what you mean by these. In particular, will they all be some sort of quantitative scale, or will be include discrete events of some description?
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**[Question 1]{.ul}**

**Additional clarity could be provided around the type of clinical pharmacist in the abstract methods. The title specifically mentions integration of the pharmacist, but I think this should also be explicit in the abstract methods.**

[Author response: ]{.ul}

The American College of Clinical Pharmacy (ACCP) defines clinical pharmacy as a 'health science discipline in which pharmacists provide patient care that optimises medication therapy, and promotes health, and disease prevention to ensure optimal patient outcomes' (1). Other studies have cited 'non-dispensing pharmacists' (2, 3) but this review cites 'clinical pharmacist' to capture remote interventions which may involve 'dispensing pharmacists'. We have added text to the abstract methods on page 2 to address this comment. 

**[Question 2]{.ul}**

**Similarly, it may be useful to expand on the definition used for integration, and to perhaps give more details regarding how the Walshe and Smith framework was operationalised, and perhaps clarifying for the reader whether all six dimensions are required without the reader having to refer to the source reference.**

[Author response:]{.ul}

Thank you for highlighting this point. We have added text to the eligibility criteria on page 5 to clarify. 

**[Further minor points:]{.ul}**

**[Question 3]{.ul}**

**Clarify whether \"nursing home\" exclusion includes residential or other supportive care environments that don\'t specifically include nursing, and how situations where the setting is unclear will be dealt with.**

[Author response:]{.ul}

A definition of nursing homes has been added to the eligibility criteria on page 4, we also outline how situations where the setting is unclear will be dealt with. 

**[Question 4]{.ul}**

**Outcomes - \"number of medicines\" should ideally be defined (although likely to vary across studies) - will it include both acute and repeat prescriptions, or account for length of treatment (e.g. chronic vs. one-off drugs)?**

[Author response:]{.ul}

A definition has been added to the main outcomes section on page 6. 

**[Question 5]{.ul}**

**The additional outcome \"clinical outcomes \[physical and mental health\]\" is very vague - some examples might help clarify what you mean by these. In particular, will they all be some sort of quantitative scale, or will be include discrete events of some description?**

[Author response:]{.ul}

We have addressed this as outlined in our response to the previous reviewer's comments and have added clarifications around these additional outcomes on page 6.

***References:***

*​​​​​​1. ACCP. DEFINITION OF CLINICAL PHARMACY accp.com \[Available from: <https://www.accp.com/stunet/compass/definition.aspx>.*

*2. Tan EC, Stewart K, Elliott RA, George J. Pharmacist services provided in general practice clinics: a systematic review and meta-analysis. Res Social Adm Pharm. 2014;10(4):608-22.*

*3. Hazen ACM, de Bont AA, Boelman L, Zwart DLM, de Gier JJ, de Wit NJ, et al. The degree of integration of non-dispensing pharmacists in primary care practice and the impact on health outcomes: A systematic review. Res Social Adm Pharm. 2018;14(3):228-40.*
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Version 1

Thank you for the opportunity to review this work. This is an area that requires more attention and the results of this systematic review may have positive consequences that promote increased utilisation of pharmacists in primary care settings to review and optimise medication regimens whilst reducing inappropriate medication use. I look forward to reading the findings of this systematic review. 

**Major Comments**

Methods: Main outcomes: Will all of the listed different medication appropriateness criteria (explicit: STOPP/START, Beer's criteria and implicit: MAI etc.) be used to assess the medication changes of each pharmacist intervention study included in this systematic review? Can the authors please comment on what will determine the use of explicit vs implicit or the use of both explicit and implicit criteria to assess the outcomes of the included studies?Additional Outcomes: More clarity is needed regarding physical and mental clinical outcomes that will be used as secondary outcome measures. Please list a few specific measures as examples. What are some key clinical outcomes that would be important to consider? (e.g. Falls? Mortality? Blood Pressure? etc.)Since the "number of medicines" is mentioned as a major outcome of this systematic review and the introduction discusses deprescribing, is the intention to focus on the reduction of the number of medicines through pharmacist medication/deprescribing medication reviews and reduction of prescribing of high-risk medications that are inappropriately prescribed, or will potential prescription omissions as defined by the START criteria also be applied? It seems the authors intend on the later since medicines optimisation is mentioned under the heading of 'Review questions' and in the title of the study. Perhaps defining the concept of optimising medicines as reducing potentially inappropriate prescribing/sub-optimal prescribing via reducing potentially inappropriate medications (PIMs) as defined by Beer's and STOPP and potential prescription omissions (PPOs) defined by START in the introduction might provide a clearer preface for the main goal of the systematic review.Analysis of subgroups: Inappropriate polypharmacy and inappropriate prescribing is a common problem in older adults. Can the authors please comment on why the cut off chosen here is patients aged 65 years old? For example, is there enough evidence for cost-effectiveness of pharmacist interventions for this age population? Also, if studies that are purely older adult focused (i.e. 65 years and older) are meant to be excluded and are outside the scope of this intended systematic review, please list this explicitly under eligibility/exclusion criteria. **Minor Comments:**

Abstract:   Methods: Can the authors please clarify what is meant by 'validated indicators'? Is STOPP/START, Beer's criteria etc. what is meant? If so, please use screening tools or criteria to assess medication appropriateness instead. Please change in the remainder of the protocol for consistency. Introduction: Lines 2-3: "Polypharmacy has commonly been defined as being on five or more medications, however recent studies have highlighted the rising prevalence of more significant polypharmacy defined as being on 10 or more medications". Whilst I agree with the content of this statement, I would recommend to: Refer to more significant polypharmacy (i.e. being prescribed or taking 10 or more medications) as hyperpolypharmacy or excessive polypharmacy as described in the literature.Please clarify that polypharmacy overall regardless of which type is on the rise in different age populations. Line 3: The referenced article does not mention the term 'complex polypharmacy', but rather the complex treatment burden associated with treating comorbidities. Please rephrase to 'polypharmacy' to remain consistent with the rest of the introduction.I would suggest combining the second paragraph beginning with "Polypharmacy is also associated with adverse drug events..." with the earlier paragraph and consolidate main concepts related to the negative consequences of polypharmacy and how polypharmacy is associated with an increased likelihood of experiencing inappropriate polypharmacy. Line 11: Please define deprescribing. Line 21: Could the authors please clarify what is meant by this systematic review will not focus on specific conditions? If previous systematic reviews focused on specific conditions (e.g. Hypertension, Diabetes etc.) could this be added to the previous sentence (line 20) that listed what other systematic reviews focused on with an appropriate reference. Methods: Eligibility criteria (line 2-3): Recommend editing "Patients will not be considered eligible if they are under the age of 18 or resident in a nursing home." to "Patients will be excluded if they are younger than 18 years old." Will pharmacist interventions in hospital settings be excluded as well? If so, please list as an exclusion criterion. Suggestion to move text currently under the Setting heading, "Clinical pharmacist interventions in a secondary or tertiary care setting will be excluded" to this section.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
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Dear Editors,

Thank you very much for the constructive comments and suggestions received from the editorial team and peer reviewers. We found the suggestions very helpful and hope we have addressed any concerns raised. We have submitted a revised version of the manuscript.

We outline the specific responses to each comment as follows:

**[​​​​​​Major Comments:]{.ul}**

**[Question 1]{.ul}**

**Main outcomes: Will all of the listed different medication appropriateness criteria (explicit: STOPP/START, Beer's criteria and implicit: MAI etc.) be used to assess the medication changes of each pharmacist intervention study included in this systematic review? Can the authors please comment on what will determine the use of explicit vs implicit or the use of both explicit and implicit criteria to assess the outcomes of the included studies?**

[Author response:]{.ul}

Thank you for highlighting this. It is not the intention in this systematic review to apply different medication appropriateness criteria to details of medications reported in the selected studies. Studies will be included in this review where they use implicit or explicit criteria for medication appropriateness as outcomes as described by study authors. The wording in the main outcomes section on page 6 has been rephrased to clarify that these will be the main outcomes where they have been used within studies.

**[Question 2]{.ul}**

**Additional Outcomes:**

**More clarity is needed regarding physical and mental clinical outcomes that will be used as secondary outcome measures. Please list a few specific measures as examples. What are some key clinical outcomes that would be important to consider? (e.g. Falls? Mortality? Blood Pressure? etc.)**

[Author response:]{.ul}

The secondary outcome measures of interest in this systematic review have been added to the additional outcomes section on page 6 to give greater clarity.

**[Question 3]{.ul}**

**Since the "number of medicines" is mentioned as a major outcome of this systematic review and the introduction discusses deprescribing, is the intention to focus on the reduction of the number of medicines through pharmacist medication/deprescribing medication reviews and reduction of prescribing of high-risk medications that are inappropriately prescribed, or will potential prescription omissions as defined by the START criteria also be applied? It seems the authors intend on the later since medicines optimisation is mentioned under the heading of 'Review questions' and in the title of the study. Perhaps defining the concept of optimising medicines as reducing potentially inappropriate prescribing/sub-optimal prescribing via reducing potentially inappropriate medications (PIMs) as defined by Beer's and STOPP and potential prescription omissions (PPOs) defined by START in the introduction might provide a clearer preface for the main goal of the systematic review.   **     

[Author response:]{.ul}             

This systematic review will not apply explicit criteria to outcomes reported by included studies, we will report a narrative synthesis of reported outcomes or a meta-analysis where data allow. We anticipate that studies of medicines optimisation may include different outcomes for medicines optimisation. Some may use number of medicines to assess medicines optimisation, which is a crude measure that does not capture the appropriateness of any medicines stopped or started. Other studies may use reduction in PIMs or PPOs defined using explicit criteria as their measure of medicines optimisation. Within the included studies, reported data on the number of medicines at trial initiation will indicate the degree of polypharmacy in study participants. Where reported at trial end, the number of medicines will capture deprescribing or instances of a missing, clinically indicated medication being commenced. The NICE guidelines on medicines optimisation recommend the adoption of the screening tools as a part of medication review processes, alongside patient-centred shared decision making and appropriate communication with the relevant health care professionals. We have added this information to the introduction section of the paper on page 3.

**[Question 4]{.ul}**

**Analysis of subgroups: Inappropriate polypharmacy and inappropriate prescribing is a common problem in older adults. Can the authors please comment on why the cut off chosen here is patients aged 65 years old? For example, is there enough evidence for cost-effectiveness of pharmacist interventions for this age population? Also, if studies that are purely older adult focused (i.e. 65 years and older) are meant to be excluded and are outside the scope of this intended systematic review, please list this explicitly under eligibility/exclusion criteria.**

[Author response:]{.ul}

Thank you for clarifying this. Older age is defined by the WHO as people aged 65 years or older (1). Polypharmacy is associated with older age (2), this age group is the population most explicit criteria of prescribing appropriateness apply to, and interventions are typically performed on this age group, as such this was selected as an appropriate cut-off for subgroup analysis. This review will include all adult patients and subgroup analysis will be conducted for the patients younger than 65 years, and those who are aged 65 years and older. The wording in the subgroup analysis section on page 8 has been changed to reflect this clarification. 

**[​​​​​​Minor Comments:]{.ul}**

**[Question 5]{.ul}**

**Abstract: **

**Methods: Can the authors please clarify what is meant by 'validated indicators'? Is STOPP/START, Beer's criteria etc. what is meant? If so, please use screening tools or criteria to assess medication appropriateness instead. Please change in the remainder of the protocol for consistency.**

[Author response:]{.ul}

Validated indicators are explicit criteria such as STOPP/START, Beers criteria, or implicit criteria such as the Medicines Appropriateness Index and Prescribing Appropriateness Index. The term validated indicators has been changed to screening tools to ensure consistency.

**[Question 6]{.ul}**

**Introduction:   Lines 2-3: "Polypharmacy has commonly been defined as being on five or more medications, however recent studies have highlighted the rising prevalence of more significant polypharmacy defined as being on 10 or more medications". Whilst I agree with the content of this statement, I would recommend to:**

**1. Refer to more significant polypharmacy (i.e. being prescribed or taking 10 or more medications) as hyperpolypharmacy or excessive polypharmacy as described in the literature.**

**2. Please clarify that polypharmacy overall regardless of which type is on the rise in different age populations.**

[Author response:]{.ul}

1\. Thank you, we have replaced the term significant polypharmacy with major polypharmacy as described in the literature (3). This review does note excessive and hyper polypharmacy, however major polypharmacy is cited as the most prevalent term.  

2\. Text has been inserted into the introduction on page 3 to clarify the prevalence of polypharmacy.

**[Question 7]{.ul}**

**Line 3: The referenced article does not mention the term 'complex polypharmacy', but rather the complex treatment burden associated with treating comorbidities. Please rephrase to 'polypharmacy' to remain consistent with the rest of the introduction.**

[Author response:]{.ul}

Text amended to 'polypharmacy' as recommended.

**[Question 8]{.ul}**

**I would suggest combining the second paragraph beginning with "Polypharmacy is also associated with adverse drug events..." with the earlier paragraph and consolidate main concepts related to the negative consequences of polypharmacy and how polypharmacy is associated with an increased likelihood of experiencing inappropriate polypharmacy.**

[Author response:]{.ul}

As per reviewer suggestions we have combined these paragraphs and consolidated the main points on page 3.

**[Question 9]{.ul}**

**Line 11: Please define deprescribing.**

[Author response:]{.ul}

Deprescribing is the process of withdrawal of an inappropriate medication, supervised by a health care professional (4). This definition has been added to the introduction section on page 3.

**[Question 10]{.ul}**

**Line 21: Could the authors please clarify what is meant by this systematic review will not focus on specific conditions? If previous systematic reviews focused on specific conditions (e.g. Hypertension, Diabetes etc.) could this be added to the previous sentence (line 20) that listed what other systematic reviews focused on with an appropriate reference.**

[Author response:]{.ul}

We have added text to the introduction section on page 3 to clarify this.

**[Question 11]{.ul}**

**Methods:**

**Eligibility criteria (line 2-3): Recommend editing "Patients will not be considered eligible if they are under the age of 18 or resident in a nursing home." to "Patients will be excluded if they are younger than 18 years old." Will pharmacist interventions in hospital settings be excluded as well? If so, please list as an exclusion criterion. Suggestion to move text currently under the Setting heading, "Clinical pharmacist interventions in a secondary or tertiary care setting will be excluded" to this section.**

[Author response:]{.ul}

We have amended the eligibility criteria on page 4 for clarity as per reviewer comments.
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